This document provides an overview of Nancy Fischer's marketing and design services, including:
1) Campaign branding, magazine advertising, website design, annual reports, marketing kits, packaging, PowerPoint presentations, and logo/icon design.
2) Concepts and final designs created for the Diprospan® brochure campaign branding.
3) Concepts developed for rebranding the Elecon® campaign, including strategic taglines and designs.
4) Multiple concepts and the final solution created for the Puregon® campaign branding.
The document analyzes and compares two soap opera trailers from EastEnders and Emmerdale. It discusses the channels they air on, their target audiences, storylines, and technical aspects like camerawork, editing, lighting, sound, and how they persuade viewers. Both target females aged 16-50 from socioeconomic classes C1 to E and use characters across age groups. Their storylines involve drama like murder and judgment. Technically, they use close-ups, slow motion, nighttime lighting, and tense soundtracks. These elements build suspense and intrigue audiences.
Trumac Healthcare - A PCD Pharma Franchise Companymohitpec
FOR PHARMA FRANCHISE IN YOUR AREA:
CONTACT: +91-9041677932
Trumac Healthcare is leading manufacturer and supplier of finished pharmaceutical medicines since last 10 years all over India. We have a wide range of product portfolio consisting of tablets, capsules, injectable, syrups, ointments, eye, ear and drops. Our products are manufactured at one of the best art of state manufacturing facilities, which are WHO and GMP certified units.
With more than 400 franchisers all over India, we are successfully catering to demands of our clients by providing them with general as well as specialty divisions like Gynaecology, Derma, Orthopaedic, Paediatric, Ophthalmic, Cardiac-Diabetic & Ayurvedic Care.
Since our inception in 2007 we have been serving hundreds of clients all over India in each and every state. Due to efforts of our clients and our employees we are selling goods worth 15 crore per year. This growth has only been possible due to our strict control over quality of our products and our sincere efforts to follow all guidelines and procedures.
We try our best to keep up to this momentum in order to serve our society for a better healthcare system.
ON PCD FRANCHISE OPPORTUNITY BASIS
This is our main model of working with our customers. PCD (Propaganda cum Distribution) is a very old concept under which parent company gives its franchise to other people in different remote areas so that the customer didn’t have to take any pain in growing company from scratch.
What we provide under our pharma franchise?
We provide our customers with monopoly rights of our company in their area so that they can sell pharma products without any competition from our company. (If you work more, you get more)
In order to help our customers to promote the products to doctors and other professionals we provide them with varieties of promotional material such as visual Aids, LBL’s, Glossary, Notepads, Catch Covers, MR Bags, Pens, Key Rings, Perfumes, Towels, reminder cards and various other sort of gifts.
The biggest advantage of working with a PCD franchise company is that you don’t have to worry about ordering the goods in large quantity. If you directly purchase from manufacturer you have to purchase in multiples of batch size which are itself very large. So your investment gets blocked in one or two products only. But in franchising model with us you can buy 25-30 medicines in the same amount which will strengthen your position in the market.
We also train our customer about the market trends and the new molecules coming in market which they should promote in order to gain high margins and results.
Benadryl cough syrup seeks to determine growth opportunities in rural markets. It was previously an Rx drug but switched to OTC. This resulted in fewer distributors and retailers carrying the brand. The document outlines problems at the company, distributor, and consumer levels including negative publicity, lack of promotion, and consumer unawareness. Suggestions include medical camps to educate consumers, social tie-ups with local clinics, incentives like branded masks, and various promotional methods like wall paintings, tickers, and tie-ins with local media and festivals to increase awareness and trust in the brand in rural areas.
This document provides a brand plan for the launch of KOF-FREE, a combination drug containing salbutamol, ambroxol, and guaifenesin. The brand plan outlines the total market size and growth rate for the drug category. It analyzes competitors and sets sales targets for the launch year. The promotional strategy includes visual aids, samples, and activities targeting pediatricians, chest specialists, and general practitioners. Financial projections estimate first year sales of Rs. 20.21 lakhs and profit after accounting for promotional expenses and costs. The long term objective is to gain 1% market share in the launch year and be a top 5 brand by 2020.
Pre-Launch Planning: Priming Your Pharma Brand For Profit And Success (mini)Eularis
In today’s environment, Pharmaceutical companies find themselves in a bind. Until recently, if drugs made over $500 Million in annual revenue within 3 to 5 years of launch, they were considered hugely successful. They were a support to an extensive company portfolio and a component of greater company profit.
However, things have changed. The standards for a successful drug have become much higher and much more dangerous. With so many revenue-producing drugs going off patent, companies are facing large holes in their balance sheets and sales that are increasingly slow.
Plus, with the stakes high and available funds low, pipelines are drying up. Add to this the closer scrutiny of safety issues, the rise of Generics, slower physician acceptance and adoption of new therapies, and the Pharma Industry is in trouble.
More and more, companies are expecting marketers to be instrumental at the key moment of launch, and marketers are under extreme pressure. To deliver on the high hopes of Pharmaceutical brand launch, companies must engage in comprehensive pre-launch planning.
In this report we analyze why launch is increasingly important, the issues involved in pre-launch planning, including key organizational strategies, marketing tactics, regulatory considerations, global issues, and methods for ensuring the most effective plans.
The document outlines the steps for effectively launching a new product which include conducting market research, developing a marketing plan, training the sales force, implementing pre-launch activities, launching the product, focusing on selling skills during and after launch, and analyzing the effectiveness of the launch.
- The document provides sales forecasts for Esoz 20, an esomeprazole magnesium tablet, for the first year in quarterly projections. It estimates sales of Rs. 2.5 crore for the year with sales increasing each month and quarter as penetration increases.
- A promotional budget of Rs. 30 lakh is allocated equally across the 4 quarters to market the brand to gastroenterologists, general physicians, surgeons and gynaecologists in metro and class 1/2 cities.
- Key activities include product sampling, branding materials, and print advertisements. Pricing is set at Rs. 15.93 per tablet with a company margin of 60% after trade discounts.
The document analyzes and compares two soap opera trailers from EastEnders and Emmerdale. It discusses the channels they air on, their target audiences, storylines, and technical aspects like camerawork, editing, lighting, sound, and how they persuade viewers. Both target females aged 16-50 from socioeconomic classes C1 to E and use characters across age groups. Their storylines involve drama like murder and judgment. Technically, they use close-ups, slow motion, nighttime lighting, and tense soundtracks. These elements build suspense and intrigue audiences.
Trumac Healthcare - A PCD Pharma Franchise Companymohitpec
FOR PHARMA FRANCHISE IN YOUR AREA:
CONTACT: +91-9041677932
Trumac Healthcare is leading manufacturer and supplier of finished pharmaceutical medicines since last 10 years all over India. We have a wide range of product portfolio consisting of tablets, capsules, injectable, syrups, ointments, eye, ear and drops. Our products are manufactured at one of the best art of state manufacturing facilities, which are WHO and GMP certified units.
With more than 400 franchisers all over India, we are successfully catering to demands of our clients by providing them with general as well as specialty divisions like Gynaecology, Derma, Orthopaedic, Paediatric, Ophthalmic, Cardiac-Diabetic & Ayurvedic Care.
Since our inception in 2007 we have been serving hundreds of clients all over India in each and every state. Due to efforts of our clients and our employees we are selling goods worth 15 crore per year. This growth has only been possible due to our strict control over quality of our products and our sincere efforts to follow all guidelines and procedures.
We try our best to keep up to this momentum in order to serve our society for a better healthcare system.
ON PCD FRANCHISE OPPORTUNITY BASIS
This is our main model of working with our customers. PCD (Propaganda cum Distribution) is a very old concept under which parent company gives its franchise to other people in different remote areas so that the customer didn’t have to take any pain in growing company from scratch.
What we provide under our pharma franchise?
We provide our customers with monopoly rights of our company in their area so that they can sell pharma products without any competition from our company. (If you work more, you get more)
In order to help our customers to promote the products to doctors and other professionals we provide them with varieties of promotional material such as visual Aids, LBL’s, Glossary, Notepads, Catch Covers, MR Bags, Pens, Key Rings, Perfumes, Towels, reminder cards and various other sort of gifts.
The biggest advantage of working with a PCD franchise company is that you don’t have to worry about ordering the goods in large quantity. If you directly purchase from manufacturer you have to purchase in multiples of batch size which are itself very large. So your investment gets blocked in one or two products only. But in franchising model with us you can buy 25-30 medicines in the same amount which will strengthen your position in the market.
We also train our customer about the market trends and the new molecules coming in market which they should promote in order to gain high margins and results.
Benadryl cough syrup seeks to determine growth opportunities in rural markets. It was previously an Rx drug but switched to OTC. This resulted in fewer distributors and retailers carrying the brand. The document outlines problems at the company, distributor, and consumer levels including negative publicity, lack of promotion, and consumer unawareness. Suggestions include medical camps to educate consumers, social tie-ups with local clinics, incentives like branded masks, and various promotional methods like wall paintings, tickers, and tie-ins with local media and festivals to increase awareness and trust in the brand in rural areas.
This document provides a brand plan for the launch of KOF-FREE, a combination drug containing salbutamol, ambroxol, and guaifenesin. The brand plan outlines the total market size and growth rate for the drug category. It analyzes competitors and sets sales targets for the launch year. The promotional strategy includes visual aids, samples, and activities targeting pediatricians, chest specialists, and general practitioners. Financial projections estimate first year sales of Rs. 20.21 lakhs and profit after accounting for promotional expenses and costs. The long term objective is to gain 1% market share in the launch year and be a top 5 brand by 2020.
Pre-Launch Planning: Priming Your Pharma Brand For Profit And Success (mini)Eularis
In today’s environment, Pharmaceutical companies find themselves in a bind. Until recently, if drugs made over $500 Million in annual revenue within 3 to 5 years of launch, they were considered hugely successful. They were a support to an extensive company portfolio and a component of greater company profit.
However, things have changed. The standards for a successful drug have become much higher and much more dangerous. With so many revenue-producing drugs going off patent, companies are facing large holes in their balance sheets and sales that are increasingly slow.
Plus, with the stakes high and available funds low, pipelines are drying up. Add to this the closer scrutiny of safety issues, the rise of Generics, slower physician acceptance and adoption of new therapies, and the Pharma Industry is in trouble.
More and more, companies are expecting marketers to be instrumental at the key moment of launch, and marketers are under extreme pressure. To deliver on the high hopes of Pharmaceutical brand launch, companies must engage in comprehensive pre-launch planning.
In this report we analyze why launch is increasingly important, the issues involved in pre-launch planning, including key organizational strategies, marketing tactics, regulatory considerations, global issues, and methods for ensuring the most effective plans.
The document outlines the steps for effectively launching a new product which include conducting market research, developing a marketing plan, training the sales force, implementing pre-launch activities, launching the product, focusing on selling skills during and after launch, and analyzing the effectiveness of the launch.
- The document provides sales forecasts for Esoz 20, an esomeprazole magnesium tablet, for the first year in quarterly projections. It estimates sales of Rs. 2.5 crore for the year with sales increasing each month and quarter as penetration increases.
- A promotional budget of Rs. 30 lakh is allocated equally across the 4 quarters to market the brand to gastroenterologists, general physicians, surgeons and gynaecologists in metro and class 1/2 cities.
- Key activities include product sampling, branding materials, and print advertisements. Pricing is set at Rs. 15.93 per tablet with a company margin of 60% after trade discounts.
Catherine Horton has worked in health and wellness for over 10 years, creating and implementing various programs. Some of her accomplishments include developing wellness programs delivered in a mobile trailer, producing team building events like dance shows and trivia games, and creating online health education classes. She has strong skills in program development, event planning, and using various media to promote wellness initiatives.
Drug Development Solutions Distinctly for the Progressive Biopharma Ventures ...Covance
This document advertises drug development services from Covance that are designed around the client's needs and goals. It highlights personalized attention from dedicated teams, collaborative engagement through ongoing communication and technology, and access to specialized scientific and regulatory expertise to help clients navigate potential issues. Clients can choose from various solutions and services at any stage of drug development, from early research through clinical trials and regulatory approval, to fit their goals and vision.
This document provides an overview of the multi-level marketing company Xango and why it may be a good opportunity. It discusses trends in health, aging, and the benefits of network marketing. Xango offers natural products like mangosteen juice and skin care that address issues like inflammation. The compensation plan aims to be fair to both full-time and part-time participants. Xango provides training and support to help people succeed with the business model.
This document provides information on LifeVantage, a company that sells supplements containing ingredients that activate the Nrf2 pathway to reduce oxidative stress. It discusses the science behind their flagship product Protandim and clinical studies supporting its ability to lower oxidative stress. It also summarizes LifeVantage's business opportunity, compensation plan, and top income earners to recruit new distributors.
Experience designer of health information. Industries include, nutraceuticals, pharmaceutical, public health, orthopedics, organic skin care, weight management, metabolism, nutrition, dietary supplements, patient, and physician education.
It is said that, "Thy food is thy medicine." Hippocrates in his writings of Modern Medicine has mentioned this fact and has clearly said that what you eat will either provide you Health or Sickness !
This document provides an overview of the multi-level marketing company Xango and its business opportunities. It discusses Xango's products like Xango Juice and Glimpse skincare, which are category creators. It also outlines the compensation plan and explains how individuals can get started by sponsoring two business partners and driving their team. The objective is to introduce potential distributors to the key elements needed for success in the MLM industry.
FLP offers a multi-level marketing opportunity providing distributors with the potential for financial freedom and a better lifestyle. Distributors can build their business from home by sharing high-quality aloe vera products and build a team to earn bonuses and commissions. The company was founded in 1978 with a vision of bringing natural wellness products and a business opportunity to help people. FLP controls the entire supply chain process for aloe to ensure product quality. Distributors have the chance to work their own schedule and earn income through retail profits, bonuses, and team commissions as they progress through the compensation plan ranks from New Distributor to Manager.
This digital magazine issue from The Veterinary Cooperative discusses managing diabetes in pets with the right products and approach. It provides tips for veterinarians to help clients understand pet diabetes since many owners are familiar with human diabetes. The issue also covers protecting business by avoiding accidental disclosure of pricing information that should remain confidential under non-disclosure agreements. Additionally, it announces upcoming webinars on diagnosing and managing adverse food reactions in pets.
A.E.I. 24 is a pharmaceutical company that licenses and exports healthcare products to over 40 countries. It offers products in five categories: dental/oral care, women's health, infant health, health and wellness, and advanced genetics. The company has a modern profile and focuses on customer interaction and developing solutions for European, Latin American, Asian, and Middle Eastern markets. It has a portfolio of over-the-counter and healthcare products and provides licensing both in and out to develop business and customer satisfaction internationally.
Nutrilite celebrates 80 years of helping people achieve better health through better nutrition. It began in 1934 when Carl F. Rehnborg introduced the first multivitamin/multimineral supplement marketed in North America. Today, Nutrilite is investing $180 million to expand its US manufacturing facilities to meet growing global demand for its vitamin and supplement products. This includes a new $81 million nutrition plant in Michigan expected to create 200 jobs. The expansion demonstrates Nutrilite's commitment to its home market and customers.
The Path to Parenthood with Pristyn Care's IVF Expertise.pptxPristyn Care Reviews
Millions of couples around the world face infertility, which can have various causes such as hormonal imbalances, structural issues, and genetic factors. Pristyn Care acknowledges the emotional impact of infertility on individuals and couples. They provide empathetic care by combining state-of-the-art medical techniques with personalized attention.
Engaging Physicians & Customers in the ExperienceRenown Health
Learn how to merge 2 or more cultures into one. Read how this is important especially as competitors become collaborators. Read how the chief physician and vice president of marketing worked together with team members, referring physicians and patients to exceed customer expectations for service and its resulting impact on increasing referrals and volumes.
The Baby-Friendly Hospital Initiative (BFHI) is a joint program between the WHO and UNICEF that promotes exclusive breastfeeding. Over 20,000 hospitals in 156 countries have been designated "Baby-Friendly" by following the Ten Steps to Successful Breastfeeding. In the US, Baby-Friendly USA oversees the designation process, though American breastfeeding rates remain low compared to other developed nations. While the BFHI has improved breastfeeding support worldwide, its impact in the US may be limited as hospitals are now incentivized by other agencies to improve breastfeeding metrics. Some argue the "Baby-Friendly" designation has become more of a marketing tool than a program focused on improving mother and baby health
This document summarizes the materials that will be provided in an oncometabolic advantage program, including:
1) A report of translational research detailing the philosophy of cancer nutrition and presenting compelling cancer nutrition research.
2) An exclusive online handbook of dietary supplements curated by experts with evidence for efficacy, verified quality, and guidance on usage.
3) Quick reference guides with practical instructions for applying the research and philosophy through diet and supplements.
4) Worksheets to analyze one's current diet and biomarkers, design a supplement protocol, and identify drug-nutrient interactions.
Imalac, Inc. is a Femtech company dedicated to helping women achieve their breastfeeding goals through innovation in the breast pump and breast pump accessory space. It has developed Nurture by Imalac, a breast pump accessory that makes a pump work better. By providing gentle, hands-free breast massage, it reduces the time it takes to pump, while increasing the amount of milk expressed.
This webinar covered oral chemotherapy options for colorectal cancer. The speaker discussed commonly used intravenous drugs as well as the two FDA-approved oral options: capecitabine and regorafenib. Capecitabine is an oral prodrug of 5-FU that is used as an alternative to intravenous 5-FU for stages II-IV disease. Regorafenib is used for metastatic colorectal cancer that has progressed on all standard therapies. The talk outlined how the drugs work, their administration schedules, common side effects, and factors to consider when determining if oral chemotherapy is appropriate. It emphasized that oral chemotherapy still requires vigilance regarding side effects and medication adherence.
Final oralchemotherapy-fightcrc-3-150311113715-conversion-gate01Sheri Pierce
This webinar covered oral chemotherapy options for colorectal cancer. The speaker discussed the commonly used drugs capecitabine and regorafenib. Capecitabine is an oral form of 5-FU that is given twice daily and can be used as adjuvant therapy or for metastatic disease. Regorafenib is used for metastatic colorectal cancer that has progressed on other therapies. Side effects and considerations for each drug were reviewed. An experimental drug, TAS-102, was also mentioned as showing promising results in clinical trials. The summary emphasized that oral chemotherapy is not suitable for all patients but can be a good option when the risks and benefits are considered individually.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Catherine Horton has worked in health and wellness for over 10 years, creating and implementing various programs. Some of her accomplishments include developing wellness programs delivered in a mobile trailer, producing team building events like dance shows and trivia games, and creating online health education classes. She has strong skills in program development, event planning, and using various media to promote wellness initiatives.
Drug Development Solutions Distinctly for the Progressive Biopharma Ventures ...Covance
This document advertises drug development services from Covance that are designed around the client's needs and goals. It highlights personalized attention from dedicated teams, collaborative engagement through ongoing communication and technology, and access to specialized scientific and regulatory expertise to help clients navigate potential issues. Clients can choose from various solutions and services at any stage of drug development, from early research through clinical trials and regulatory approval, to fit their goals and vision.
This document provides an overview of the multi-level marketing company Xango and why it may be a good opportunity. It discusses trends in health, aging, and the benefits of network marketing. Xango offers natural products like mangosteen juice and skin care that address issues like inflammation. The compensation plan aims to be fair to both full-time and part-time participants. Xango provides training and support to help people succeed with the business model.
This document provides information on LifeVantage, a company that sells supplements containing ingredients that activate the Nrf2 pathway to reduce oxidative stress. It discusses the science behind their flagship product Protandim and clinical studies supporting its ability to lower oxidative stress. It also summarizes LifeVantage's business opportunity, compensation plan, and top income earners to recruit new distributors.
Experience designer of health information. Industries include, nutraceuticals, pharmaceutical, public health, orthopedics, organic skin care, weight management, metabolism, nutrition, dietary supplements, patient, and physician education.
It is said that, "Thy food is thy medicine." Hippocrates in his writings of Modern Medicine has mentioned this fact and has clearly said that what you eat will either provide you Health or Sickness !
This document provides an overview of the multi-level marketing company Xango and its business opportunities. It discusses Xango's products like Xango Juice and Glimpse skincare, which are category creators. It also outlines the compensation plan and explains how individuals can get started by sponsoring two business partners and driving their team. The objective is to introduce potential distributors to the key elements needed for success in the MLM industry.
FLP offers a multi-level marketing opportunity providing distributors with the potential for financial freedom and a better lifestyle. Distributors can build their business from home by sharing high-quality aloe vera products and build a team to earn bonuses and commissions. The company was founded in 1978 with a vision of bringing natural wellness products and a business opportunity to help people. FLP controls the entire supply chain process for aloe to ensure product quality. Distributors have the chance to work their own schedule and earn income through retail profits, bonuses, and team commissions as they progress through the compensation plan ranks from New Distributor to Manager.
This digital magazine issue from The Veterinary Cooperative discusses managing diabetes in pets with the right products and approach. It provides tips for veterinarians to help clients understand pet diabetes since many owners are familiar with human diabetes. The issue also covers protecting business by avoiding accidental disclosure of pricing information that should remain confidential under non-disclosure agreements. Additionally, it announces upcoming webinars on diagnosing and managing adverse food reactions in pets.
A.E.I. 24 is a pharmaceutical company that licenses and exports healthcare products to over 40 countries. It offers products in five categories: dental/oral care, women's health, infant health, health and wellness, and advanced genetics. The company has a modern profile and focuses on customer interaction and developing solutions for European, Latin American, Asian, and Middle Eastern markets. It has a portfolio of over-the-counter and healthcare products and provides licensing both in and out to develop business and customer satisfaction internationally.
Nutrilite celebrates 80 years of helping people achieve better health through better nutrition. It began in 1934 when Carl F. Rehnborg introduced the first multivitamin/multimineral supplement marketed in North America. Today, Nutrilite is investing $180 million to expand its US manufacturing facilities to meet growing global demand for its vitamin and supplement products. This includes a new $81 million nutrition plant in Michigan expected to create 200 jobs. The expansion demonstrates Nutrilite's commitment to its home market and customers.
The Path to Parenthood with Pristyn Care's IVF Expertise.pptxPristyn Care Reviews
Millions of couples around the world face infertility, which can have various causes such as hormonal imbalances, structural issues, and genetic factors. Pristyn Care acknowledges the emotional impact of infertility on individuals and couples. They provide empathetic care by combining state-of-the-art medical techniques with personalized attention.
Engaging Physicians & Customers in the ExperienceRenown Health
Learn how to merge 2 or more cultures into one. Read how this is important especially as competitors become collaborators. Read how the chief physician and vice president of marketing worked together with team members, referring physicians and patients to exceed customer expectations for service and its resulting impact on increasing referrals and volumes.
The Baby-Friendly Hospital Initiative (BFHI) is a joint program between the WHO and UNICEF that promotes exclusive breastfeeding. Over 20,000 hospitals in 156 countries have been designated "Baby-Friendly" by following the Ten Steps to Successful Breastfeeding. In the US, Baby-Friendly USA oversees the designation process, though American breastfeeding rates remain low compared to other developed nations. While the BFHI has improved breastfeeding support worldwide, its impact in the US may be limited as hospitals are now incentivized by other agencies to improve breastfeeding metrics. Some argue the "Baby-Friendly" designation has become more of a marketing tool than a program focused on improving mother and baby health
This document summarizes the materials that will be provided in an oncometabolic advantage program, including:
1) A report of translational research detailing the philosophy of cancer nutrition and presenting compelling cancer nutrition research.
2) An exclusive online handbook of dietary supplements curated by experts with evidence for efficacy, verified quality, and guidance on usage.
3) Quick reference guides with practical instructions for applying the research and philosophy through diet and supplements.
4) Worksheets to analyze one's current diet and biomarkers, design a supplement protocol, and identify drug-nutrient interactions.
Imalac, Inc. is a Femtech company dedicated to helping women achieve their breastfeeding goals through innovation in the breast pump and breast pump accessory space. It has developed Nurture by Imalac, a breast pump accessory that makes a pump work better. By providing gentle, hands-free breast massage, it reduces the time it takes to pump, while increasing the amount of milk expressed.
This webinar covered oral chemotherapy options for colorectal cancer. The speaker discussed commonly used intravenous drugs as well as the two FDA-approved oral options: capecitabine and regorafenib. Capecitabine is an oral prodrug of 5-FU that is used as an alternative to intravenous 5-FU for stages II-IV disease. Regorafenib is used for metastatic colorectal cancer that has progressed on all standard therapies. The talk outlined how the drugs work, their administration schedules, common side effects, and factors to consider when determining if oral chemotherapy is appropriate. It emphasized that oral chemotherapy still requires vigilance regarding side effects and medication adherence.
Final oralchemotherapy-fightcrc-3-150311113715-conversion-gate01Sheri Pierce
This webinar covered oral chemotherapy options for colorectal cancer. The speaker discussed the commonly used drugs capecitabine and regorafenib. Capecitabine is an oral form of 5-FU that is given twice daily and can be used as adjuvant therapy or for metastatic disease. Regorafenib is used for metastatic colorectal cancer that has progressed on other therapies. Side effects and considerations for each drug were reviewed. An experimental drug, TAS-102, was also mentioned as showing promising results in clinical trials. The summary emphasized that oral chemotherapy is not suitable for all patients but can be a good option when the risks and benefits are considered individually.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
2. Diprospan® Concepts and Final Brochure
Campaign Branding
1
For pa in du e t o inF l a mmation ,
Diprospan
®
prospan
®
24 to 48 Hours postinjection
injection
Local anesthe ic
gives mmed ate
re ief by mask ng
pain
4 to 8 Hours
pos injection
24 to 48 Hours
pos injection
Anes het c wears
o f and pain
may eturn
L ng-act ng cort cos ero ds
may begin to prov de
el ef of pa n
only diprospan®
beg ns to reduce inflammation with n
1 to 2 hours prov des long lasting relief
Fast aCtinG
Betamethasone sodium
phosphate begins to
reduce inflammation within
1 to 2 hours before
anes he ic wears o f
s
Long La ting ReLief
Betamethasone
acetate p ovides
sustained relief
Celestone® Soluspan® indication The intra articular or soft tissue
administ ation of CELESTONE® SOLUSPAN® Injectable Suspension is indicated
as adjunctive therapy for short term administ ation (to ide he patient over an
acute episode or exacerba ion) in acute gouty ar hri is acute and subacute bur
s tis acute nonspec fic tenosynov tis
epicondy itis rheumatoid arthr tis synovi is of osteoar h itis
Important Safety Informa ion As w th any potent corticosteroid adverse events
have been associated w th CELESTONE® SOLUSPAN® including flu d and electro
lyte disturbances as we l as adve se reactions involving the following systems
a lergic reactions cardiovascular dermatologic
endocrine gast ointestinal metabolic musculoskeletal neurological/psychiatric
and ophthalmic Corticosteroids may also affect immune response
CELESTONE® SOLUSPAN® should not be administered intravenously or used in
systemic fungal infections Vaccination administration of live or ive attenuated
vaccines is contraindicated in patients eceiving
immunosupp essive doses of corticosteroids
Please see accompanying fu l P esc ibing Informa ion
W I D E LY AVA I L A B L E
d
lonG last nG
W I D E LY AVA I L A B L E
Long L
ing R Lie
Design and create three
concepts. Client chose
solution and designed
layed out and produced
final solution. Models
were selected and
managed in photoshoot.
ONLY Diprospan
ONLY Diprospan
Fast relief
...that lasts
The ONLY injectable corticosteroid product
with a unique dual-agent formulation
Betamethasone sodium phosphate provides fast onset of action
Betamethasone acetate provides sustained relief
Proven safe and effective, with over 40 years
of clinical experience
When the pain of
inflammation
demands fast relief...
ONLY Diprospan begins to
reduce inflammation in 1-2 hours
before anesthetic wears off
Ava lable in a multi-dose 5-mL vial
Other long-acting
corticosteroids
Inject on
Inject on
Anesthet c
Anesthetic
Betamethasone
Sodium Phosphate
1 2 hrs
hrs
REL EF
PAIN
PAIN
Betamethasone
Acetate
Inject on
Fast relief that lasts.
Betamethasone
Long Act ng
Co ticosteroid
Betamethasone
sodium phosphate aceta e
Anesthetic
gives mmediate Begins to reduce
Provides
rel ef by masking inflammation in
sustained relief
pain
1 2 hours before
anesthet c wears off
Inject on
Pain
In 4 8 hours
Anesthetic
gives immediate post injection
rel ef by masking pa n returns
pain
Long Act ng
Cort cos eroid
Beg ns to work
24 48 hours
post in ect on
Fast relief that lasts.
3. Campaign Branding
2
Elecon® Branding Concepts
AVOID THE STRUGGLE BETWEEN EFFICACY AND SAFETY
FOR EFFICACY AND SAFETY TOGETHER CHOOSE ELOCON
Efficacy and safety go better together.
Efficacy and safety tied together
NO NEED TO CHOOSE YOUR DIRECTION WITH ELECON IT’S CLEAR
(side effects)
( e f f i c a cy )
LESS IS MORE
This concept needs a tagiline.
The s mple steroid choice for efficacy + safety
Concepts and designs for rebranding
of the. Elecon® campaign. Worked with
writers to come up with strategic ideas.
4. Campaign Branding
3
Puregon® Concepts and Final Solution
Puregon Delivers
The Proof is in
the Numbers
The proof is in
the numbers
Proven efficacy in
the largest IVF clinical
trial ever conducted.
• Proven results 38%
ongoing pregnancy rate
• Exce lent pregnancy rates
regardless of endogenous LH levels
• Optimal dosing flexibi ity
patient friendly device
• Rich heritage of qua ity
and innovation
Proven efficacy in the largest
IVF clinical trial ever conducted.
38% Proven efficacy in world’s
largest IVF clinical trial
• Proven results 38% ongoing pregnancy rate
• Proven results 38% ongoing pregnancy rate
• Exce lent pregnancy rates regardless of
• Excellent pregnancy rates regardless of
endogenous LH levels
• Optimal dosing flexibi ity patient friendly device
• Rich heritage of qua ity and innovation
A million successes
and counting.
endogenous LH levels
A million successes
and counting.
• Optimal dosing flexib lity patient friendly device
• Rich heritage of quality and innovation
Living Proof
Proven efficacy in the largest
IVF clinical trial ever conducted.
• Proven resu ts – 38% ongoing pregnancy rate
Excellent pregnancy rates regardless of
endogenous LH levels
Optimal dosing flexibi ity, patient friendly device
• Rich her tage of quality and innovation
Proven results. Powerful heritage.
A m llion successes
and counting
Assuring the
Donovan
Family Tree
Lives On
Proven efficacy in the largest
IVF clinical trial ever conducted.
Proven resu ts 38% ongoing pregnancy rate
Excellent pregnancy rates regardless of
endogenous LH levels
Optimal dosing flex bility, patient friendly device
Rich her tage of quality and innovation
Giving Life to a New Generation.
Design and create concepts.
Took clients chosen selection
and created full campaign.
8. Web Banners / Digital Development
Women’s Health, NuvaRing® and Celestone®
Design for
email blast
campaign.
Designed and created all artwork for banners.
On these pop-up and web banners ensured files
were seamless for usage.
Designed interface
for Women’s Health,
comparative website
for NuvaRing®.
Created all banner and layout of content for
these email blasts.
7
9. Web Development
FX Concepts and Prolifics Websites
8
www.fx-concepts.com
Redesigned entire website from the
start to finish. Developed and presented
concepts, created all layered artwork
and worked with programmers to
insure seamless graphics and
navigation for user.
www.prolifics.com
Refreshed existing website. Developed
and presented concepts to client.
Created all layered artwork and worked
with programmers to insure seamless
graphics and navigation for user.
10. Conference Graphics
KPMG Summer Shindig
9
MONTVALE’S
Summer
I !
SHINDOGY’S THE DAY!
T DA
Designed and
developed final
concept and
artwork for
Summer Shindig
mer !
Sum DIG
MO
’S
VALE
NT
HIN
S
er
mm IG!
Su
D
MO
’S
VALE
NT
HIN
S
!
HEF
AC
IT’S
Montvale Café
Monday, June 18
12:30 p.m.
e
Ther
u
ee Yo
S
Thursday, June 28
3:30 p.m. – 7:30 p.m.
12. White Paper
Create annual
whitepaper and look
for marketing
materials for outlook
survey. Develop charts
and montage images
as requested by client.
KPMG Forensic Technology Brochure
11
M&A Out ook Su vey | 4
3 | M&A Ou look Survey
presented by
2013 M&A
Outlook Survey
Executives Expect
M&A Market to
be Active in the
Year Ahead
Growth Opportunities Motivate Deals
Wh ch factors wi l be motivating these deal-makers?
Respondents sa d hat the number one reason for mak ng
an acqu s tion was to expand their company’s geog aph c
reach 20 percent). Other important reasons ncluded PE
buyers seeking profitable operations 19 percent), enter ng
into a new line of bus ness (17 percen ), and expanding
their customer base (15 percent). Several respondents a so
noted that sel ers seem more real st c about valuat ons and
deal prices had gotten more attractive. One respondent
said he thought his company wou d do more deals in 2013
because of “more reasonab e seller expectations” and
another noted “very low pr ces.”
Primary Deal Motivators
kpmg.com
Expand geograph c each
F nanc al buyer ook ng for
prof tab e oper tions and/or
ga n on exit
En er in o new l nes of bus ness
Expand cus omer base
Last year saw several blockbuster deals, including Softbank’s
$20.1 bi lion bid for a stake in Sprint Nextel and Nest e’s
$11.9 bi lion deal for Pf zer’s infant nutr tion unit. However,
the midd e-market remained the most active sector.
Respondents conf rmed that deal s ze s expected to remain
on the sma ler s ze. Seventy-nine percent of respondents said
that they expected the r dea s to be valued at $250 mi l on
or ess. (By compar son, n last year’s survey, 68 percent of
respondents sa d the r deals wou d come in at $250 m llion
or ess.) Twelve percent of espondents said the r companies
wou d be nvolved in dea s valued between $250 mi l on
and $499 mi lion and ess than two percent sa d their
companies would be doing deals valued between $1 bi l on
and $5 billion. KPMG’s Phil Isom, princ pal and U.S. leader
for its Corporate Finance and Restructuring practice sa d the
survey results are consistent with what he s seeing in the
marketplace. “Midd e market deals continue o be the most
active. G ven the smaller valuation ranges, and shareho der
base ( requen ly owned and operated by en repreneurs or
management team), they are eas er to f nance and get across
the f n sh line despite a st ll somewhat unce ta n economy,”
he sa d. “ n add tion, many restructuring opportun ties sti l
exist n th s segment.”
Deal Size Stays Small
In terms of which industr es would be most act ve n
2013 and beyond, respondents expected software/
telecommunications/technology to be the most act ve
sector (39 percent), fol owed by hea thcare pharmaceut cals
(35 percent), energy 31 percent), and financial serv ces
(20 percent).3 KPMG’s Moyers agreed that technology and
healthcare will continue to be at ractive, especially for PE
investors. “The constantly evolving world of technology, and
investment opportunit es hat arise as we get more c arity
around Obamacare, will create attract ve opportunities in
those sec ors,” he said.
The vast major ty of respondents (73 percent) expect
North America to be the most popular deal dest nat on.
Other reg ons where M&A s expected to be obust
are Western Europe (28 percen ), Ch na (27 percent),
Braz l (20 percent), and Asia, excluding Ch na and Ind a
(19 percent).4 Tiemann explained, “Nor h America’s re at ve
fiscal health and recovering consumer marke s make t a
popular nvestment destinat on. The European debt crisis
w ll also create investment opportun ties, especially in
the distressed sector. And the growth prospects of the
emerging markets make them almost necessary deal
locations or firms seeking revenue growth.”
Industries with the Most Activity
Most Popular Regions
Software/ elecommun cat ons/
technology
Nor h Ame ica
Heal hcare/pharmaceu ica s
Energy
Western Eu ope
Financial se vices
China
ndus r al products
Consumer p oduc s/ ood and
beverage
Braz l
E ect on cs
Pro ess onal serv ces
e g aw fi ms
accoun ing i ms etc )
In roduce new produc s
As a (not inc uding
China or nd a)
Automot ve
Dep oy cap tal
South Amer ca
(not nclud ng B azi )
Transporta ion
Less than $250 mi l on
Eastern Europe
(not includ ng Russ a)
Chemica s
Enhance nte lec ual proper y
$250 m l on to $499 mi l on
Re ail
India
O her
Other
$500 mi ion to $999 mi l on
Med a
B ing in house another
funct on n he supp y cha n
M dd e East Af ica
Gove nmen /h gher educat on/
not for p of t
0%
5%
10%
15%
20%
25%
$1 bi l on o $5 bi l on
0%
10%
20%
30%
Russia
40%
0%
20%
40%
60%
80%
100%
Grea er han $5 bi l on
0%
0
P
P
P
A special supp ement to Mergers & Acquisitions
P
P
P
P
PP
20%
40%
60%
80%
Mu tip e responses permit ed
Mu tip e responses permit ed
P
0
P
P
P
P
9
P
PP
9
M&A Ou look Survey | 6
5 | M&A Ou look Survey
Corporate Buyers have a Slight Edge
Due Diligence Remains Key
Although deal-makers were gene a ly optimistic about
activity eve s, they did c te several concerns and noted that
due diligence remained even more mportant in today’s
volati e environment. Almost two th rds (62 percent) of
survey respondents noted that they thought deal activity
wou d be most inh bi ed by recess onary fea s and a s ow
growth environment. Other issues they thought would
s ow deal low included uncerta nty su rounding tax code
changes (31 percent), conce ns about Europe (23 percent),
and regulatory considerations 21 percen ).5
Factors Inhibiting Deal Activity
Recessiona y fea s/s ow
grow h envi onment
Unce ta n y su rounding
ax code changes
Concerns about European
econom c s tua ion
Regu atory cons dera ions
Avai ab l ty nd or cost of
debt f nancing
Effect of unemployment
on consumer demand
Stock pr ce vo ati ty
O her
0% 10% 20% 30% 40% 50% 60% 70%
P
P
P
P
“It is also crucial to analyze tax ssues and implicat ons
as pa t of the due dil gence process,” acco ding to L sa
Madden, KPMG’s leader of M&A Tax. “Over the last
several years, he e has been a large degree of uncertainty
concerning tax ssues and buyers need to have a thorough
understanding of how d fferent tax outcomes might a fect
their dea s and deal s ructures,” she said. The vast major ty
of respondents agree: they do consider tax impl cations at
the outset of a deal (69 percent). Another 28 percent sa d
that tax ssues are cons dered after key deal terms and
structures are f nal zed.
P
When asked wh ch ex t strategy would be preferred
by sel ers in 2013, 65 percent of respondents sa d hey
thought companies would prefer to se l to a st ateg c
buyer. Eighteen percent said they thought sellers would
pre er to sell to a f nancial buyer, 13 percent said they
thought companies would choose to ref nance or raise
debt cap tal, and hree percent sa d that companies would
pre er an IPO.
Corporates vs. PE Buyers
Corpora e buyers
Pr vate equ ty buyers
t s always nteresting o try to determine who wi l have an
edge when seek ng out the most valuable targe s. In light
of he responses g ven to p eferred exit strategies, t s not
surpr sing that according to 44 percent of respondents,
corporate buyers have a slight advantage n the current deal
env ronment. Thirty percent sa d they thought PE buyers
wou d have the advan age and 17 percent said ne ther wou d
have an advantage.8 Corporate buyers would most likely
have an advantage because they would have g eater synergy
opportunit es and thus be able o pay a higher pr ce n an
auct on s tuat on.
Nei her wi l have n advantage
Don t know
0%
10%
20%
30%
40%
Conclusion
The last few years have provided the M&A market and the economy in general with
many challenges. More certainty around U.S. fiscal and tax policy and movement on
the European debt crisis should further so idify consumer confidence and improve
global economic prospects. Despite the fact that uncertainty st ll ex sts, dealmakers
are cautiously optimistic and the vast majority of them said they will be seeking growth
opportunities through acquisitions this year. An improving M&A market should begin
to take shape in 2013 and extend into the near future.
The rema nder of responden s had no op n on
Mul iple esponses pe mitted
Mul iple esponses pe mitted
Mu tiple responses permi ted
P
In terms of due diligence, responden s said the r greater
challenges were presen ed by the assessment or
volatility for future revenue streams (43 percent). Other
important cha lenges ncluded assess ng the target’s
quality of earn ngs (31 percent), revenue and cost syne gy
analys s (25 percent), and ssues surround ng the cultural
assessment of the target (21 percent).6
Simi arly, ntegration issues also present s gnificant
cha lenges and should be analyzed during the due diligence
stage of a deal. The most s gnif cant integrat on ssues
for respondents were cultural ssues (38 percent), closely
fo lowed by human capital issues (36 percent), operat onal
and rat onalization ssues (34 pe cent), and issues ar s ng
from ntegrating products and serv ces and accounting
systems (both 17 percent).7
L ck of sui ab e oppor unit es
0
P
P
P
P
PP
9
P
0
P
P
P
P
P
P
P
PP
9
P
50%
13. Redesign and
layout for
specialized
forensic brochure
applied as a template
for new materials.
KPMG Forensic Technology Brochure
3
12
• Data co lection strategies
• Data f ltering and cu l ng strateg es ( ncluding keyword search)
• Incorporating review resul s into ongoing collect on and
fil ering/cull ng s rategy
• Data stratification and sampling
• Custodian-based prioritization and sampling
• Systems-based pr or tizat on and sampl ng
• Ident ficat on of multi-l ngual documen s
KPMG helped us with a large
e-discovery project in the context
of bet-the-company l tigation.
Beginning to end, they shined.
KPMG’s workflow allowed us
to quickly and inexpensively cull
terabytes of data into a tight set
of documents for case analysis
and production. KPMG’s metrics
and sampling procedures
assured us that we had done so
accurately and reliably. And we
found KPMG’s proprietary
review software—with advanced
analytics and machine-assisted
review—to be state of the art.
More generally, KPMG has
emerged as one of the leaders
and visionaries in the e-discovery
industry. We would not hesitate
to work with them again.
kpmg.com
ELECTRON C DISCOVERY
ELECTRONIC DISCOVERY
KPMG’s proven workf ows to foster effect veness and
productivity nclude:
KPMG
Enterprise
Level
Electronic
Discovery
KPMG Enterpr se Level
KPMG Enterprise Level
Process, Review and Produce
600 gigabytes in Two Weeks
In this matter, KPMG’s c ient elected to move
forward w th technology assisted review because
they needed immediate access to the most like y
re evant documents and did not have t me to perform
linear review on the who e data set, which included
600 gigabytes of data from 31 custodians, representing
2 5 mil ion documents.
KMPG project managers worked with the cl ent and
its law firm to tra n the relevance ranking engine,
determ ne statistically appropriate cutoff l nes for
document review, identify and select the appropriate
sample s ze to test and validate their dec sion to
withhold and not rev ew documents that had been
categorized as irrelevant.
The process started with the law firm’s review team
reviewing approximately 100 000 documents in order
to train the relevance rank ng engine. Then KPMG
ran a l 2.5 mi lion documents through its predictive
coding process, analyzing all documents based on the
tra ning document set. The results were the relevance
ranking appl ed to the documents, w th only the most
re evant documents being immed ate y reviewed by
the law firm n a l near review process, the middleranked group be ng held in batches for further rev ew,
and only a random samp e rom the owest-ranked
group reviewed for qual ty assurance.
As a result, the c ient and its f rm were able to meet its
production deadl ne in only two weeks.
The KPMG-managed serv ces approach to elect on c d scovery
is premised on a phased me hodo ogy that seeks to reduce the
volume of data at each step in the p ocess while demonstrating
soundness and defensibility. As such, we generally:
Defensibly reducing the document set at each stage reduces
the cost of the subsequent stage—and all other downstream
stages. The savings can be extraordinary.
In a recent matter, KPMG applied ts Techno ogy Assisted
Rev ew process to a corpus of hundreds of thousands of
documents and was ab e to reduce the overall cost to review
the documents from an estimated $447,000 to less than
$98 000—a reduction of 78%.
Leading Technology enables our process,
a lowing us to quickly implement changes that wi l
benefit our user base broadly, or to create custom
implementations for specific client needs
KPMG s committed to providing outstand ng e ectronic
discovery too s. In many instances, we have developed
ndustry- eading applicat ons to del ver the best poss b e
solution to he client need. In other cases, we provide process
and technical exce lence around leading third-party tools.
Discovery Radar® Co lector
KPMG’s D scovery Radar Collec or DRC™) is a targeted
co lection application that reduces the amount of ESI co lected
during l tigat on and o her matters, wh ch n turn reduces
p ocess ng and rev ew costs downstream. It is a se f-conta ned
executable application that requires no ins a lation, can be
launched f om a network share or thumb drive and can be
used by remo e desktop to perform long distance col ection for
p eservation or rev ew.
Using DRC facilitates co lections of data and documents that
are most relevant to a matter. By using his approach, ess data
is co lected up front, reduc ng the overa l process ng costs,
and review costs. A targeted col ection approach s a so more
cost e fective and reduces the risk of collecting data that isn’t
relevant to the cu rent matter, but, once preserved, may have
to be reta ned f it becomes relevant to another.
Data collect on capabil ty includes:
• Ema l
• Native documents
KPMG’s Propr etary Tools
Global Evidence Tracking System
4
®
• W k s
KPMG has bu lt our Global Evidence T ack ng System (GETS) to
track both physical and og cal evidence from co lection through
the processing and product on stages. It prov des a consistent
and systemat c collation of digital evidence, preservation of
processed da a, and documentat on of the chain of custody.
It a so del vers integ ated ev dence processing notificat ons
and data handl ng specif cations.
• Calendar tems
GETS ncludes a task history eature that provides a detailed
status and history of each item of ev dence— ncluding file
counts and time stamps for each stage n the process—for
audit, metrics and productivity measurement. The resu t is a
transparent view of he corpus of evidence and processes that
the corpus s undergo ng. GETS s a cr tical tool in support ng
client driven priorities to select he order in which evidence is
processed and rev ewed.
• Other data sources.
• Contacts
• Tasks
• Attachments
• M crosoft SharePoint®
• Preserve more than we collect
• Collect more than we p ocess
• Process more than we ingest nto techno ogical tools
• Ingest more than we submit for manual review
– Attorney
Leading International Law F rm
5
KPMG Enterprise Level
KPMG Enterpr se Level
ELECTRONIC DISCOVERY
ELECTRONIC DISCOVERY
Techno ogy Assisted Review/Pred ctive Coding
Technology assisted review helps o reduce overall project
cost by mak ng human review more accurate and efficient.
Using technology can a so help a team get to the most relevant
data fas er, streamlining the review, and he p ng to reduce
overa l rev ew costs, wh ch a e typ cally the most expensive
component of discovery.
Discovery Radar®
KPMG’s proprietary enterpr se d scovery lifecyc e management
appl cation, Discovery Radar, of ers advanced functional ty
w thin a single environment el m nating the issues caused by
moving data from one platform o another.
Rev ew of Documents – Review, Analysis and Production
The Discovery Radar rev ew module p ovides fu l-text
search ng, fi ter ng and document rev ew capabilities and
supports hosted native f le review, hosted image eview n
TIFF or PDF format, and a hosted hybr d review that consists of
native and TIFF fi e review.
KPMG has fully integrated Equ v o>Relevance techno ogy
nto its D scovery Radar platform to analyze these arge
volumes of data and efficiently rank documents. A elevance
ranked rev ew leverages the know edge and experience of
a Subject Matter Expert (SME) across the document corpus
based on an ite at ve train ng process. The software ranks the
relevance of the selected document popu at on based on the
SME eviewer’s feedback on samples of documen s, resu ting
n efficiencies and mitiga ed risks throughout the l tigat on and
nvestigation process.
• Pre-filtering by custod an, metadata, fi e type, date range,
keywords and de-dupl cation
• Tagg ng, redact ng, Bates stamp ng and exporting n
document sets
• Fu l document rev ew functionality with effic ency too s or
both the document rev ew admin strator as we l as nd v dual
document rev ewers
• Issue coding, annotating, redacting, pr nting, and
down oad ng as nat ve f les
• Stat stical sampl ng capab l ty throughout the appl cation
(early case assessment, quality control, ver ficat on of
technology-assisted review resu ts, etc.)
All operations a e tracked and subject o D scovery Radar’s
robust, customizable report ng on user act ons, productivity,
and rev ew management metrics.
“KPMG has been positioned
by Gartner, Inc., in the
Visionaries Quadrant of the
analyst organization’s 2012
Magic Quadrant for e-Discovery
Software report.”
– Gartner Inc Mag c Quadrant for
E Discove y Sof ware Debra Logan
Shei a Ch lds May 24 2012
Relevance Review Model
Subject ma ter expe t
ev ews a samp e
Staff attorneys con irm
result ng relevant documents
®
D scovery Radar delivers:
• Fu l endorsement and product on capab l ties
6
Review Optimizat on
D scovery Radar was bu lt to facil tate the fastest and h ghest
quality eview poss b e. Search capabilities include “fuzzy
search,” which accommodates for word variances (due to
misspe lings or OCR ssues). In addition, a l documents
are processed so that various “Re ated Documents”
( .e , attachments, exact dupl cates, near-duplica es, other
messages in the thread) can be d splayed as shown here
and organized n batches.
D scovery Radar’s f lter ng capabil ties a low for qu ckly
dentifying documents that are not responsive or relevant.
Our clients can easily stratify the corpus of documents by
us ng sea ch terms, conversation threads, document similarity
groups and concept search. With accelerated reviews
cl en s can enhance rev ew quality, enr ch keyword lists, and
effectively reduce costs and manage resources by rev ewing
ess data.
Gartner does not endo se any vendor p oduct or se vice depic ed in its research
publ cat ons and does not adv se technology users to select only those vendors
with the highest rat ngs Gartner research publ cations cons st of the op n ons of
Gartner s research o gan zat on and shou d not be cons rued as sta emen s of fact
Gartner disc aims all wa rant es expressed or imp ied wi h respect o th s research
ncluding any warran ies of merchantabi ty or f tness for a par icular purpose
KPMG has bu lt n attr bute sampling for the discovery process
n order to fac litate Techno ogy Assisted Rev ew and pred ct ve
coding. Our sampling tools and methodology, wh ch can
also be applied n other areas of eview, he p our clients
meet search-eff c ency and quality assurance goals, increase
productivity, and reduce costs wh le mainta ning or even
mproving defens b lity.
Contract at o neys perform
inal reviews on sma ler set
of less relevant documents
Low relevance documen s cou d be sampled
and inear review costs avoided wi h minimal r sk
Audit History and Report ng
The D scovery Radar Aud t History feature improves
defensibility and transparency by tracking actions performed by
reviewers and other users to ndividual documents dur ng the
d scovery process.
KPMG’s work process procedures to manage document
review and electronic discovery are enhanced by the DR Report
Writer. With n Report Writer, custom reports can be created o
monitor and manage document reviewer metr cs, productivity
and document/work product d sposition.
KPMG believes in always recommend ng the best tool for
our client s part cular set of ci cumstances. In cases where
KPMG s proprietary echnology is not the best option, or to
suit a cl ent s preferences, KPMG also supports best-of-breed
th rd-party too s such as Nuix®, Attenex Patterns®, C earwell®,
Re at v ty® and Encase®.
“
“We elected to move forward w th
technology assisted review because
we needed immediate access to the
most likely relevant documents and
did not have time to perform inear
review on the whole data set .
It has been and continues to be our
experience that when used on the
proper type of data, by the appropriate
team of professionals, this technology
works. You guys made it easy.”
“
Brochure
--Shareholder, 120-Attorney Law Firm
15. ANNUAL REPORT
Amstar Funds Report
Created new branding, designed
logo and applied look and feel
to all new collateral.
14
16. ANNUAL REPORT
15
Pamrapo Bankcorp, Inc.
Designed layouts for
annual report. Client chosen
selection was taken from
concept to completion.
17. Marketing Kit
Samsung Electronics / Professional Products Group
Concepted, designed and
developed marketing kit from
start to completion. Implemented
design on all additional collateral.
16
18. Packaging Design
17
No Nut Nation®
T
THE PERFEC
THE PERFECT
BROWNIE
BROWNIE
6 individually wrapped Brownies
6 Individually
Wrapped
Brownies
NET WT. 6.3 OZ
(179g)
6 Individually
Wrapped Brownies
NO TREE NUTS. NO PEANUTS. NO WORRIES.
THE PERFEC T BR
Branding, logo
development, design
and implementation of
full packaging for
nut-free brownies and
other deserts.
OWNIE
THE PERFEC T BR
6 Individually
Wrapped Brownies
NO TREE NUTS. NO PEANUTS. NO WORRIES.
Th
BROWNIE
THE PERFEC T
N
NO TREE NUTS. NO PEANUTS. NO WORRIES.
Serving Size 1 b ownie (75g)
Servings Per Conta ner 6
Amount Per Serving
Calories from Fat 170
% Daily Value*
Total Fat 19g
Saturated Fat 11g
Trans Fat 0g
Cholesterol 80mg
Sodium 110mg
Total Carbohydrate 38g
Die ary Fiber 2g
Sugars 29g
Prote n 4g
Vitam n A 6%
Calcium 2%
•
•
29%
55%
27%
5%
13%
8%
THE PERFECT
BROWNIE
ii
F
s
Co Size 1 brown Milk, Wheat, Soy.
rv ng t ins Egg, (75g)
t i
Our strict allergen protocol includes manufacturing on dedicated nut free
equipment in a nut free facility and batch testing for the absence of the
o s
C re r
F t 7
peanut protein for added assurance.
29%
www.nonutnation.com
V tamin C 0%
Iron 6%
Not actual size
6 individually wrapped Brownies
Serving suggestion
Keep frozen and thaw
before serving
NET WT 15 9 OZ (450g)
No Nut Nation LLC
6 Individually
Wrapped Brownies
NO TREE NUTS. NO PEANUTS. NO WORRIES.
No Tree Nuts No Peanuts No Worries
No Nut Nation desserts are made with the finest, natural ingredients from
carefully selected suppliers with safe, nut free practices. Ingredients: Sugar,
Eggs, Semi-sweet Chocolate Chips [Sugar, Chocolate Liquor, Anhydrous
Dextrose, Cocoa Butter, Soya Lecithin (Emulsifier), Ground Vanilla Beans],
Butter, Unbleached Enriched Wheat Flour, Unsweetened Baking Chocolate
(natural chocolate liquor), Vanilla Extract, Salt.
*Pe cent Da ly Values a e based on a 2 000 calo ie diet Your da ly
values may be higher or lower depending on your calories needs
Calories
2 000
2 500
Total Fat
Less Than
65g
80g
Satu ated Fat
Less Than
20g
25g
Cholesterol
Less Than
300mg
300mg
Sodium
Less Than
2 400mg 2 400mg
Total Carbohydrate
300g
375g
Dieta y Fiber
25g
30g
Calories per gram
Fat 9 • Ca bohydrate 4 • Protein 4
NET WT. 6.3 OZ (179g)
6 Individually
Wrapped Brownies
NO TREE NUTS. NO PEANUTS. NO WORRIES.
The Perfect Brownie
Nutrition Facts
Calories 310
OWNIE
Waldwick, NJ 07463
THE PERFECT
BROWNIE
6 individually wrapped Brownies
NO TREE NUTS. NO PEANUTS. NO WORRIES.
19. Powerpoint Presentation
Powerpoint concepts to be
implemented in full presentation.
Logo design and Powerpoint concepts
were implemented in full presentation.
Remicade® and Global Leadership Presentation
18
20. Logo / icon Design
Corporate Identifiers for Merck
19
I N T E R F A I T H CENTER ON
CORPORATE RESPONSIBILITY
I N T E R F A I T H CENTER ON
COR PO R AT E RESPONSIBILITY
Logo concepts
and final design for
Merck marketing.
INTERFAITH
CENTER ON
CORPORATE
RESPONSIBILITY